Belgian biopharmaceutical company Cardio3 Biosciences, which is backed by a consortium of venture capital firms, has announced that it is considering listing new shares in an IPO.
The company, which raised €19m last month from existing investors in the form of €7m in fresh equity and €12m as a conversion of convertible loans, hopes to raise new funds through an IPO on NYSE...
GP closes fundraising activity for its food-dedicated veicle after three years on the market
Deal will fund the launch of the online aggregation and price comparison platform's insurance products
The £5m growth funding was provided together with Hargreave Hale
Indufin is taking over from ING as the main investor in the software group